Health Care • Biotechnology: Pharmaceutical Preparations
$45.05 ▼ -0.03
(-0.07%)
MKT CAP: $1.89B • VOL: 426.4K
52W L $15 52W H $50
ROARABLE / RQD
D • 44/100
PIOTROSKI
2 / 9
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$38
MEDIAN
$50
MEAN
$51
HIGH
$61
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE TRAX TAPE
TRAX // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $54.51 | $51.81 | 2025-02-14 | $41.00 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $56.76 | $53.16 | 2025-02-06 | $42.35 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $51.36 | $49.55 | 2025-01-29 | $43.25 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $45.95 | — | 2025-01-17 | $44.15 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $39.64 | $42.80 | 2025-01-09 | $40.09 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $53.61 | $46.85 | 2024-12-18 | $39.19 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $43.70 | $45.50 | 2024-12-04 | $41.90 | -4.3% | 48% | C |